November 19, 2021
Santen Pharmaceutical and ActualEyes, a Kyoto-based biotech startup originating from Doshisha University, said on November 18 that they have inked an agreement to jointly conduct a PII clinical trial on sirolimus eye drops for treating Fuchs endothelial corneal dystrophy (FECD)...read more